Hutchmed (HCM) said late Thursday it will receive a milestone payment after partner Takeda (TAK) launched Fruzaqla capsules in Japan as a therapy for metastatic colorectal cancer.
The launch follows approval for the manufacturing and sale of Fruzaqla by Japan's Ministry of Health, Labour and Welfare.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments